# Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

> **NCT00801801** · PHASE2 · TERMINATED · sponsor: **Francisco Robert,MD** · enrollment: 5 (actual)

## Conditions studied

- Non Squamous Cell Lung Cancer
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Docetaxel + Sorafenib

## Key facts

- **NCT ID:** NCT00801801
- **Lead sponsor:** Francisco Robert,MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2009-10
- **Final completion:** 2011-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Sponsors withdrew funding; preliminary efficacy data was not encouraging.
- **Last updated:** 2017-05-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801801, "Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00801801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*